These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 12830723)
1. [Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion]. He L; Wang GL; Zhang Q Yao Xue Xue Bao; 2003 Mar; 38(3):227-30. PubMed ID: 12830723 [TBL] [Abstract][Full Text] [Related]
2. An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. Zhang XN; Tang LH; Gong JH; Yan XY; Zhang Q PDA J Pharm Sci Technol; 2006; 60(2):89-94. PubMed ID: 16696191 [TBL] [Abstract][Full Text] [Related]
3. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. He L; Wang GL; Zhang Q Int J Pharm; 2003 Jan; 250(1):45-50. PubMed ID: 12480272 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021 [TBL] [Abstract][Full Text] [Related]
5. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Park JH; Park JH; Hur HJ; Woo JS; Lee HJ Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604 [TBL] [Abstract][Full Text] [Related]
6. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Nornoo AO; Chow DS Int J Pharm; 2008 Feb; 349(1-2):117-23. PubMed ID: 17869458 [TBL] [Abstract][Full Text] [Related]
7. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Nornoo AO; Zheng H; Lopes LB; Johnson-Restrepo B; Kannan K; Reed R Eur J Pharm Biopharm; 2009 Feb; 71(2):310-7. PubMed ID: 18793723 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Li R; Eun JS; Lee MK Arch Pharm Res; 2011 Feb; 34(2):331-7. PubMed ID: 21380818 [TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462 [TBL] [Abstract][Full Text] [Related]
10. Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? Shord SS; Camp JR Biopharm Drug Dispos; 2006 May; 27(4):191-6. PubMed ID: 16566060 [TBL] [Abstract][Full Text] [Related]
11. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349 [TBL] [Abstract][Full Text] [Related]
12. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. Zhang HY; Tang X; Li HY; Liu XL Int J Pharm; 2008 Feb; 348(1-2):70-9. PubMed ID: 17719191 [TBL] [Abstract][Full Text] [Related]
13. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Rodrigues DG; Maria DA; Fernandes DC; Valduga CJ; Couto RD; Ibañez OC; Maranhão RC Cancer Chemother Pharmacol; 2005 Jun; 55(6):565-76. PubMed ID: 15726368 [TBL] [Abstract][Full Text] [Related]
14. [Comparative study on pharmacokinetics and tissue distribution of a novel microemulsion based on the paclitaxel/L-OH lipid complex and paclitaxel injection in cremophor]. Ma YL; Ye J; Zhang PX; Xia XJ; Liu YL Yao Xue Xue Bao; 2013 Nov; 48(11):1698-704. PubMed ID: 24475708 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. Bayindir ZS; Be AB; Yüksel N Turk J Med Sci; 2015; 45(6):1403-12. PubMed ID: 26775401 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718 [TBL] [Abstract][Full Text] [Related]
18. Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. Lee EH; Lee SH; Park DY; Ki KH; Lee EK; Lee DH; Noh GJ Anesthesiology; 2008 Sep; 109(3):436-47. PubMed ID: 18719441 [TBL] [Abstract][Full Text] [Related]
19. Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. Ye M; Zhu Z; Fu Q; Shen K; Li DK Acta Pharmacol Sin; 2000 Jul; 21(7):596-9. PubMed ID: 11360664 [TBL] [Abstract][Full Text] [Related]
20. An oil-free microemulsion for intravenous delivery of diallyl trisulfide: formulation and evaluation. Li X; Yue Y; Zhou Y; Fan Y; Fan C; Huang Y; Wu F; Liu Y Int J Pharm; 2011 Apr; 407(1-2):158-66. PubMed ID: 21238561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]